Title : Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.

Pub. Date : 2019 Aug

PMID : 30872116






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 LOBP has been attributed to beta2-adrenergic receptor (B2AR) downregulation, a process requiring farnesylation, which is inhibited by alendronate. Alendronate adrenoceptor beta 2 Homo sapiens
2 LOBP has been attributed to beta2-adrenergic receptor (B2AR) downregulation, a process requiring farnesylation, which is inhibited by alendronate. Alendronate adrenoceptor beta 2 Homo sapiens
3 The after/before ICS plus LABA treatment ratio of B2AR number was 1.0 for alendronate (P = .86) and 0.8 for placebo (P = .15; P = .31 for difference between treatments). Alendronate adrenoceptor beta 2 Homo sapiens
4 The B2AR signaling ratio was 0.89 for alendronate (P = .43) and 1.02 for placebo (P = .84; P = .44 for difference). Alendronate adrenoceptor beta 2 Homo sapiens